Jade Biosciences (NASDAQ:JBIO – Get Free Report) and Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.
Insider and Institutional Ownership
5.6% of Ensysce Biosciences shares are held by institutional investors. 24.9% of Jade Biosciences shares are held by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and target prices for Jade Biosciences and Ensysce Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jade Biosciences | 1 | 1 | 5 | 2 | 2.89 |
| Ensysce Biosciences | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Jade Biosciences and Ensysce Biosciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jade Biosciences | N/A | N/A | -$127.41 million | ($4.61) | -4.18 |
| Ensysce Biosciences | N/A | N/A | -$10.18 million | ($4.22) | -0.13 |
Jade Biosciences is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Jade Biosciences and Ensysce Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jade Biosciences | N/A | -46.55% | -42.99% |
| Ensysce Biosciences | -200.87% | -426.62% | -195.53% |
Volatility & Risk
Jade Biosciences has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.
Summary
Jade Biosciences beats Ensysce Biosciences on 8 of the 13 factors compared between the two stocks.
About Jade Biosciences
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
About Ensysce Biosciences
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.
Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
